(a) Multivariable Cox regression models in HER2-positive patients since 2006
| Characteristic | Overall survival (n = 516, events = 53) | ||
|---|---|---|---|
| HR | 95% CI | P value | |
| Trastuzumab + CHT + AHT (n = 180, events = 4) |
Reference | — | — |
| CHT + AHT (n = 35, events = 2) |
2.34 | 0.43; 13.38 | 0.32 |
| Trastuzumab + CHT (n = 91, events = 6) |
3.80 | 0.87; 16.59 | 0.08 |
| AHT (n = 106, events = 17) |
4.28 | 1.30; 14.05 | 0.017 |
| CHT (n = 24, events = 3) |
9.50 | 1.90; 47.43 | 0.006 |
| No adjuvant therapy (n = 80, events = 21) |
10.44 | 3.02; 36.06 | <0.001 |
Model is controlled for age, Ki67 categories, tumor size, nodal status, grading, and receptor status; HR: hazard ratio; 95% CI: 95% confidence interval.